Duality Biotherapeutics, Inc. (HKG:9606)
Hong Kong · Delayed Price · Currency is HKD 172.20
-11.70 (-6.36%)
Sep 10, 2026, 1:14 PM HKT
Duality Biotherapeutics Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Cash & Equivalents | 2,265 | 1,276 | 1,209 | 1,131 |
Short-Term Investments | 673.15 | 2,005 | 188.06 | 5.26 |
Trading Asset Securities | 97.8 | 99.14 | - | - |
Cash & Short-Term Investments | 3,036 | 3,380 | 1,397 | 1,136 |
Cash Growth | -18.10% | 141.97% | 22.96% | - |
Accounts Receivable | 147.88 | 277.92 | 379.02 | 100.8 |
Other Receivables | 32.06 | 39.92 | 70.44 | 32.55 |
Receivables | 179.93 | 317.84 | 449.46 | 133.35 |
Restricted Cash | 67.82 | 49.71 | 45.16 | 42.65 |
Other Current Assets | 180.25 | 86.37 | 18.26 | 21.75 |
Total Current Assets | 3,464 | 3,834 | 1,910 | 1,334 |
Property, Plant & Equipment | 30.9 | 28.68 | 18.6 | 17.76 |
Other Intangible Assets | 3.07 | 3.77 | 46.24 | 54.25 |
Other Long-Term Assets | 8.39 | 26.28 | 115.56 | 94.01 |
Total Assets | 3,507 | 3,893 | 2,090 | 1,500 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Accounts Payable | 1,024 | 761.94 | 670.91 | 234.81 |
Accrued Expenses | - | 60.44 | 38.97 | 25.24 |
Short-Term Debt | 239.01 | 141.06 | - | - |
Current Portion of Leases | 4.05 | 4.81 | 2.99 | 2.91 |
Current Income Taxes Payable | - | 2.29 | 1.72 | 0.92 |
Current Unearned Revenue | 347.43 | 77.77 | 90.26 | 156.13 |
Other Current Liabilities | 127.85 | 3.57 | 3,067 | 2,141 |
Total Current Liabilities | 1,742 | 1,052 | 3,872 | 2,561 |
Long-Term Leases | 2.76 | 3.91 | 2.3 | 2.41 |
Long-Term Unearned Revenue | 7.88 | 240.92 | 238.25 | 60.16 |
Other Long-Term Liabilities | 169.53 | 169.53 | - | - |
Total Liabilities | 2,056 | 1,466 | 4,112 | 2,624 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Common Stock | 0.07 | 0.06 | 0.01 | 0.01 |
Additional Paid-In Capital | - | 6,987 | - | - |
Retained Earnings | -5,772 | -4,750 | -2,161 | -1,111 |
Comprehensive Income & Other | 7,291 | 189.27 | 133.26 | -19.2 |
Total Common Equity | 1,451 | 2,427 | -2,028 | -1,130 |
Shareholders' Equity | 1,451 | 2,427 | -2,022 | -1,124 |
Total Liabilities & Equity | 3,507 | 3,893 | 2,090 | 1,500 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Total Debt | 379.46 | 149.78 | 5.29 | 5.32 |
Net Cash (Debt) | 2,657 | 3,230 | 1,392 | 1,131 |
Net Cash Growth | -27.00% | 132.13% | 23.07% | - |
Net Cash Per Share | 29.71 | 49.58 | 173.96 | 141.35 |
Filing Date Shares Outstanding | 90.25 | 89.42 | 8 | 8 |
Total Common Shares Outstanding | 90.25 | 89.42 | 8 | 8 |
Working Capital | 1,722 | 2,782 | -1,962 | -1,227 |
Book Value Per Share | 16.08 | 27.14 | -253.46 | -141.22 |
Tangible Book Value | 1,448 | 2,423 | -2,074 | -1,184 |
Tangible Book Value Per Share | 16.04 | 27.10 | -259.24 | -148.00 |
Machinery | - | 19.8 | 10.74 | 7.61 |
Construction In Progress | - | 1.3 | 0.55 | 0.19 |
Leasehold Improvements | - | 8.75 | 6.92 | 6.33 |